Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.

Taro MawatariR MuraokaY Iwamoto

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2016)

Therapeutic response in elderly patients is consistent, but early initiation of risedronate treatment may help prevent fractures. Risedronate-induced increase in BMD is lower in patients with vitamin D deficiency, suggesting that vitamin D supplementation is important to achieve optimal treatment response.

Keyphrases

phase iii
clinical trial
electronic health record
big data
bone mineral density
combination therapy
oxidative stress
phase ii
drug induced
deep learning